A
A
A

China Adds Million-Yuan CAR-T Therapy to National Reimbursement List, Signalling Shift in Biotech Licensing Dynamics

·11/16/2026
China's latest update to its national drug reimbursement list carries implications beyond expanding patient access to innovative medicines. By agreeing to reimburse a CAR-T therapy that previously cost more than RMB 1 million per treatment, the government is sending a broader signal that domestically developed innovative drugs can secure commercial returns in the Chinese market. The move could gradually reshape how local biotech companies approach early-stage licensing deals with multinational pharmaceutical companies.

Released on November 14, the 2026 National Reimbursement Drug List (NRDL) added 107 medicines, including a record 51 Class 1 innovative drugs. Among the most notable additions was relmacabtagene autoleucel, a CAR-T cell therapy developed by JW Therapeutics for the treatment of lymphoma. Previously priced at more than RMB 1 million per infusion, the therapy becomes the first CAR-T product to enter China's basic medical insurance reimbursement system. Following price negotiations, patients' out-of-pocket costs are expected to fall below RMB 100,000.

Separately, China's new commercial health insurance innovative drug list added 12 medicines, bringing the total number of products covered to 28. Notably, the list includes the world's first CAR-T therapy for solid tumours, developed by CARsgen Therapeutics.Approved in June, the therapy secured inclusion in the commercial insurance list in less than five months.

Professor Chen Yi, a health policy researcher at Tsinghua University, told PharmaDJ that the principal constraint facing China's innovative drug industry has been the ability to secure payment and market access, rather than the capacity to conduct research and develop new medicines.

For much of the past decade, Chen said,a defining feature of China's innovative drug industry has been the early-stage licensing of promising assets to multinational pharmaceutical companies. Often described as the "seedling sale" model, this approach reflected the difficulties domestic Chinese biotech companies faced in generating sufficient commercial returns from the local market to sustain costly research and development programmes.

The 2022 licensing agreement between China's Akeso and US-based Summit Therapeutics for ivonescimab, a PD-1/VEGF bispecific antibody, illustrated the scale of this model. The deal, valued at up to $5 billion plus royalties, gave Summit development and commercialisation rights in major markets outside China and subsequently became one of the most prominent examples of China's emerging role as a source of innovative drug candidates for global pharmaceutical development.

With reimbursement increasingly available for innovative therapies, biotech companies may be able to advance their assets further through clinical development before seeking international partners. For some programmes, they may also have greater scope to pursue independent development and commercialisation strategies. As Chen Yi emphasised, the objective is not to discourage international partnerships or limit companies to the domestic market, but to establish a stronger home-market foundation from which Chinese innovators can compete globally.

Chen said that China continues to operate primarily as a high-volume, relatively low-price pharmaceutical market, while the US remains the world's largest and most commercially attractive market for many innovative medicines. The substantial pricing gap between the two markets is unlikely to narrow through reimbursement policy adjustments alone. Meanwhile, the commercial insurance innovative drug list, despite its expansion, still covers a relatively small proportion of the population.

Market access also extends beyond reimbursement approval. A notice issued by four Chinese government ministries on November 10, aimed at facilitating hospital access to innovative medicines, highlights another persistent challenge: securing inclusion on reimbursement lists does not automatically guarantee availability through hospital formularies and pharmacy systems.

Taken together, these policy developments point to a gradual evolution in China's pharmaceutical market. The government is seeking to balance cost containment with the need to support innovation, while expanding the commercial pathways available to domestically developed medicines.
Download